Drug class
Recombinant human alpha-galactosidase A; enzyme replacement therapy (ERT) biologic
Mechanism of action
Provides exogenous alpha-galactosidase A activity to hydrolyse globotriaosylceramide (GL-3) and related glycosphingolipid substrates that accumulate because of deficient endogenous enzyme activity in Fabry disease. Agalsidase alfa and agalsidase beta are distinct recombinant products; the exact product should be identified before product-specific use is assigned.
General use cases
- Long-term enzyme replacement therapy for patients with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency); dosing, age eligibility and product information are specific to agalsidase alfa or beta
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
